HUE068061T2 - WEE1 inhibitor vegyület kristályos formája és felhasználása - Google Patents
WEE1 inhibitor vegyület kristályos formája és felhasználásaInfo
- Publication number
- HUE068061T2 HUE068061T2 HUE20798924A HUE20798924A HUE068061T2 HU E068061 T2 HUE068061 T2 HU E068061T2 HU E20798924 A HUE20798924 A HU E20798924A HU E20798924 A HUE20798924 A HU E20798924A HU E068061 T2 HUE068061 T2 HU E068061T2
- Authority
- HU
- Hungary
- Prior art keywords
- crystal form
- inhibitor compound
- wee1 inhibitor
- wee1
- compound
- Prior art date
Links
- 101100102932 Xenopus laevis wee2-b gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910364694 | 2019-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE068061T2 true HUE068061T2 (hu) | 2024-12-28 |
Family
ID=73029676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE20798924A HUE068061T2 (hu) | 2019-04-30 | 2020-04-30 | WEE1 inhibitor vegyület kristályos formája és felhasználása |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12291536B2 (enExample) |
| EP (1) | EP3964510B1 (enExample) |
| JP (1) | JP7582970B2 (enExample) |
| CN (1) | CN113784968B (enExample) |
| AU (1) | AU2020266956B2 (enExample) |
| BR (1) | BR112021021230A8 (enExample) |
| CA (1) | CA3138240C (enExample) |
| DK (1) | DK3964510T3 (enExample) |
| ES (1) | ES2984617T3 (enExample) |
| FI (1) | FI3964510T3 (enExample) |
| HR (1) | HRP20241008T1 (enExample) |
| HU (1) | HUE068061T2 (enExample) |
| IL (1) | IL287472A (enExample) |
| LT (1) | LT3964510T (enExample) |
| PL (1) | PL3964510T3 (enExample) |
| PT (1) | PT3964510T (enExample) |
| RS (1) | RS65747B1 (enExample) |
| SG (1) | SG11202111315XA (enExample) |
| SI (1) | SI3964510T1 (enExample) |
| SM (1) | SMT202400303T1 (enExample) |
| WO (1) | WO2020221358A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| RU2496780C2 (ru) | 2006-10-27 | 2013-10-27 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Твердые формы |
| JP5411847B2 (ja) * | 2007-04-25 | 2014-02-12 | Ｍｓｄ株式会社 | Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 |
| WO2009054332A1 (ja) | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| SI2477628T1 (sl) | 2009-09-15 | 2014-11-28 | Merck Sharp & Dohme Corp. | Priprava oblik kristalinskega hemihidrata dihidropirazolopirimidinona |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| WO2013012681A1 (en) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| US9181239B2 (en) | 2011-10-20 | 2015-11-10 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| US9718821B2 (en) | 2012-02-23 | 2017-08-01 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| AU2016344040B2 (en) | 2015-11-01 | 2020-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
| WO2018171633A1 (zh) * | 2017-03-23 | 2018-09-27 | 上海迪诺医药科技有限公司 | 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用 |
| EP3712150B1 (en) * | 2017-11-01 | 2024-06-12 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Macrocyclic compound serving as wee1 inhibitor and applications thereof |
| JP7481336B2 (ja) | 2018-10-26 | 2024-05-10 | ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド | Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用 |
-
2020
- 2020-04-30 PT PT207989245T patent/PT3964510T/pt unknown
- 2020-04-30 WO PCT/CN2020/088451 patent/WO2020221358A1/zh not_active Ceased
- 2020-04-30 LT LTEPPCT/CN2020/088451T patent/LT3964510T/lt unknown
- 2020-04-30 US US17/607,447 patent/US12291536B2/en active Active
- 2020-04-30 RS RS20240816A patent/RS65747B1/sr unknown
- 2020-04-30 HR HRP20241008TT patent/HRP20241008T1/hr unknown
- 2020-04-30 EP EP20798924.5A patent/EP3964510B1/en active Active
- 2020-04-30 SG SG11202111315XA patent/SG11202111315XA/en unknown
- 2020-04-30 FI FIEP20798924.5T patent/FI3964510T3/fi active
- 2020-04-30 JP JP2021564588A patent/JP7582970B2/ja active Active
- 2020-04-30 SM SM20240303T patent/SMT202400303T1/it unknown
- 2020-04-30 BR BR112021021230A patent/BR112021021230A8/pt unknown
- 2020-04-30 SI SI202030468T patent/SI3964510T1/sl unknown
- 2020-04-30 AU AU2020266956A patent/AU2020266956B2/en active Active
- 2020-04-30 PL PL20798924.5T patent/PL3964510T3/pl unknown
- 2020-04-30 ES ES20798924T patent/ES2984617T3/es active Active
- 2020-04-30 CN CN202080031816.4A patent/CN113784968B/zh active Active
- 2020-04-30 CA CA3138240A patent/CA3138240C/en active Active
- 2020-04-30 HU HUE20798924A patent/HUE068061T2/hu unknown
- 2020-04-30 DK DK20798924.5T patent/DK3964510T3/da active
-
2021
- 2021-10-21 IL IL287472A patent/IL287472A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2984617T3 (es) | 2024-10-30 |
| BR112021021230A8 (pt) | 2023-04-25 |
| CA3138240A1 (en) | 2020-11-05 |
| HRP20241008T1 (hr) | 2024-11-08 |
| SG11202111315XA (en) | 2021-11-29 |
| EP3964510A1 (en) | 2022-03-09 |
| RS65747B1 (sr) | 2024-08-30 |
| PT3964510T (pt) | 2024-07-29 |
| WO2020221358A1 (zh) | 2020-11-05 |
| AU2020266956B2 (en) | 2025-05-08 |
| EP3964510B1 (en) | 2024-07-03 |
| LT3964510T (lt) | 2024-08-12 |
| DK3964510T3 (da) | 2024-07-29 |
| CN113784968A (zh) | 2021-12-10 |
| CN113784968B (zh) | 2024-03-15 |
| SI3964510T1 (sl) | 2024-10-30 |
| JP2022530812A (ja) | 2022-07-01 |
| BR112021021230A2 (enExample) | 2021-12-21 |
| EP3964510A4 (en) | 2023-04-26 |
| AU2020266956A1 (en) | 2021-10-28 |
| FI3964510T3 (fi) | 2024-07-24 |
| PL3964510T3 (pl) | 2024-08-19 |
| US12291536B2 (en) | 2025-05-06 |
| CA3138240C (en) | 2025-04-01 |
| JP7582970B2 (ja) | 2024-11-13 |
| US20220220120A1 (en) | 2022-07-14 |
| IL287472A (en) | 2021-12-01 |
| SMT202400303T1 (it) | 2024-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287472A (en) | Crystalline form of wee1 inhibitory compound and use thereof | |
| ZA202106511B (en) | Jak inhibitor compound and use thereof | |
| EP4056563A4 (en) | COMPOUND AS A SHP2 INHIBITOR AND USE THEREOF | |
| IL290106A (en) | A crystalline form of an atr inhibitor and its use | |
| EP4349838A4 (en) | WEE1 INHIBITOR AND ITS USE | |
| SG11202109438TA (en) | A salt and crystal form of a fak inhibitor | |
| ZA202100923B (en) | Crystal form of lanosterol prodrug compound and application thereof | |
| ZA202109737B (en) | Compound used as kinase inhibitor and application thereof | |
| IL308476A (en) | Inhibitors of the menin-mil interaction | |
| IL276312B1 (en) | Use of Alkoxypyrazoles as nitrification inhibitors | |
| EP3774708A4 (en) | Foxm1 inhibitor compositions and methods of using the same | |
| EP4063366A4 (en) | CRYSTAL FORM OF NUCLEOPROTEIN INHIBITOR AND USE THEREOF | |
| IL285219A (en) | A crystal of the compound diarylthiohydantoin | |
| PL3670611T3 (pl) | Środek antykorozyjny do zabezpieczania wnęk i jego zastosowanie | |
| ZA202107810B (en) | Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof | |
| GB2589398B (en) | Compounds and methods of use | |
| ZA202101589B (en) | Crystal form of tri-cycle compound and application thereof | |
| IL291368A (en) | Inhibits expression of methadherin | |
| EP3845534A4 (en) | SALT FORM AND CRYSTALLINE FORM OF A NEW AZATRICYCLIC COMPOUND AND USE THEREOF | |
| EP3737945A4 (en) | NEW USE OF KIRREL2 AND A KIRREL2 INHIBITOR | |
| EP3957634A4 (en) | CRYSTALLINE FORM OF SGLT INHIBITOR AND ITS APPLICATION | |
| EP4023648A4 (en) | CARCINOGENIC FUSIONED KINASE HIBITOR CRYSTAL AND APPLICATIONS THEREOF | |
| HK40045217A (zh) | 激酶抑制剂化合物和组合物及使用方法 | |
| GB201908573D0 (en) | Compounds and methods of use | |
| AU2019900605A0 (en) | Inhibitors of necroptosis |